Effect of Intravenous Mannitol on Anterior Chamber Depth and Intraocular Pressure.

Effect of Intravenous Mannitol on Anterior Chamber Depth and Intraocular Pressure in Patients Before Cataract Surgery.

Status

Completed

Phases

Unknown

Study type

Interventional

Source

ClinicalTrials.gov

Registry ID

NCT07605260

Enrollment

Registered

2026-05-22

Start date

2026-01-01

Completion date

2026-06-30

Last updated

2026-07-22

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Cataract

Brief summary

Local data regarding the effectiveness and safety of mannitol has been scarce. Therefore, the current study was planned, aiming to compare the change in mean anterior chamber depth and intraocular pressure (IOP) and to determine the frequencies of perioperative complications during cataract surgery in groups receiving mannitol versus placebo.

Detailed description

The literature shows that the effectiveness of mannitol in decreasing intraocular pressure (IOP) varies widely. Although it rapidly lowers IOP in the majority of people, clinical results and the extent of the reduction differ depending on a number of factors. Mannitol can be detrimental for patients with pulmonary edema or severe heart failure (congestive heart failure) because it quickly draws fluid into the bloodstream, increasing intravascular volume. In addition to contributing to the local literature, the results of this study will aid in determining the true efficacy and safety of mannitol.

Interventions

DRUGMannitol

After employing standard protocol for dilatation, intravenous mannitol at 1g/kg over a period of 30 minutes was administered to the patients.

DRUGPlacebo

After employing standard protocol for dilatation, patients were given a placebo.

Study design

Allocation

NON_RANDOMIZED

Intervention model

PARALLEL

Primary purpose

TREATMENT

Masking

NONE

Eligibility

Sex/Gender

ALL

Age

30 Years to 80 Years

Healthy volunteers

Inclusion criteria

* Patients of any gender * Aged 30-80 years * Undergoing cataract surgery

Exclusion criteria

* Patients with glaucoma, uveitis, or corneal pathology * With trauma * Previously had surgery * With exfoliation syndrome * Had iridotomies * Had use of sympathetic α1 antagonist

Design outcomes

Primary

Measure	Time frame	Description
Change in the intraocular pressure	45 minutes	The change in the intraocular pressure, measured in mmHg, was noted at post-intervention and compared to the baseline.
Change in the anterior chamber depth	45 minutes	The change in the anterior chamber depth, measured in mm, was noted at post-intervention and compared to the baseline.

Countries

Pakistan

Contacts

PRINCIPAL_INVESTIGATORMuhammad Irtiza

Pakistan Air Force (PAF) Hospital Islamabad

STUDY_DIRECTORMuhammad Azam, FCPS